Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer.

Ettinger, David S; Jotte, Robert; Lorigan, Paul; Gupta, Vicram; Garbo, Lawrence; Alemany, Carlos; Conkling, Paul; Spigel, David R; Dudek, Arkadiusz Z; Shah, Chirag; Salgia, Ravi; McNally, Richard; Renschler, Markus F; Oliver, Jennifer W

Ettinger, David S; Jotte, Robert; Lorigan, Paul; Gupta, Vicram; Garbo, Lawrence; Alemany, Carlos; Conkling, Paul; Spigel, David R; Dudek, Arkadiusz Z; Shah, Chirag; Salgia, Ravi; McNally, Richard; Renschler, Markus F; Oliver, Jennifer W.

Affiliation

Ettinger DS; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA. ettinda@jhmi.edu

J Clin Oncol ; 28(15): 2598-603, 2010 May 20.

Article in En | MEDLINE | ID: mdl-20385980

Subject(s)

Anthracyclines/therapeutic use; Antineoplastic Agents/therapeutic use; Lung Neoplasms/drug therapy; Small Cell Lung Carcinoma/drug therapy; Adult; Anthracyclines/adverse effects; Antineoplastic Agents/adverse effects; Disease-Free Survival; Female; Humans; Lung Neoplasms/pathology; Male; Middle Aged; Small Cell Lung Carcinoma/pathology; Survival Analysis; Treatment Outcome; Young Adult

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Anthracyclines / Small Cell Lung Carcinoma / Lung Neoplasms / Antineoplastic Agents Type of study: Clinical_trials Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: J Clin Oncol Year: 2010 Document type: Article Affiliation country: United States Country of publication: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google